Processa Pharmaceuticals, Inc. · NASDAQ:PCSA
Processa Pharmaceuticals — Investor Presentation (October 2023)
14 slides from Processa Pharmaceuticals's investor presentation, Oct 16, 2023
Slide 1: Next Generation Chemotherapy: Improved Treatment for More Patients
@ Processa Pharmaceuticals Next Generation Chemotherapy: Improved Treatment for More Patients Corporate Presentation October 2023
Slide 2: Forward Looking Statement and Disclosures
Forward Looking Statement and Disclosures @ Processa Pharmaceuticals This presentation includes forward-looking statements based upon our current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predi
Slide 3: About Processa Pharmaceuticals
About Processa Pharmaceuticals @ Provessa Pharmaceuticals Next-Generation Chemotherapies (NGCs) Designed to Improve Survival and Quality of Life for Cancer Patients * Ade-risked strategy of developing new chemical entities (NCEs) based on improving pharmacokinetics of existing, proven treatments. *
Slide 4: Processa Senior Management
Processa Senior Management George Ng Chief Executive Officer Joined Processa 2023, Former Roles: President, COO, & Director, Cali Biotherapeuties + Partner, PENG Life Science Ventures Founderand President Scilex Pharmaceuticals JD, University of Notre Dame; B.A. Dual Degree, University of California
Slide 5: Oncology Opportunity
Oncology Opportunity * More than 200,000 new cancer diagnoses worldwide across multiple indications for each NGC in development. * NGC compounds will potentially address efficacy and toxicity at an optimized dose to show improvement over standard of care. * Development process aligns with FDA’s Onco
Slide 6: Processa's Pipeline
Processa’s Pipeline @ Provessa Pharmaceuticals Next Generation Chemotherapies Improving Safety and Efficacy Development Stage Drug Cancer Indications Preclin Phase 1 Phase 2 Phase 3 NDA Next Generation Hepatocellular, Pancreatic, REG riesc Compieti Capecitabine Colorectal, Breast, Gastric, & ieee <o
Slide 7: How Our Oncology Assets Differ from Current Chemotherapy
@ Processa Pharmaceuticals How Our Oncology Assets Differ from Current Chemotherapy Standard of Care Problem Potential Patient Benefits with Our NGCs Capecitabine — Low treatment response with high side effect profile. Gemcitabine —High drug resistance and/or acquired resistance; administered as IV.
Slide 8: PCS6422 / Next Generation Capecitabine (NGC-Cap)
@ Provessa Pharmaceuticals PCS6422 / Next Generation Capecitabine (NGC-Cap) a * Alters metabolism to increase distribution of 5-FU and cancer-killing molecules to cancer cells while reducing the metabolites that only cause side effects Effi . seri erat Mee * Active molecule same as Capecitabine but
Slide 9: PCS3117 / Next Generation Gemcitabine (NGC-Gem)
Efficacy Side Effects Clinical Development NASDAQ: PCSA PCS3117 / Next Generation Gemcitabine (NGC-Gem) Oral Drug with Same MOA as Gemcitabine @ Provessa Pharmaceuticals Provides improved treatment over Gemcitabine seen in previous pancreatic cancer trial data; cancer cells exposed to more NGC-Gem c
Slide 10: PCS11T / Next Generation Irinotecan (NGC-Iri)
@ Provessa Pharmaceuticals PCS11T / Next Generation Irinotecan (NGC-Iri) * Active molecule SN-38 is same active molecule in Irinotecan Efficacy * Distributes SN-38 differently, entering the cell membrane of cancer cells preferentially over normal cells, improving cancer-killing effect * Given MNM-SN
Slide 11: Summary of Activities/Milestones
Summary of Activities/Milestones @ Processa Pharmaceutical Milestone Approx. Date NGC-Cap: Complete Phase 1B MTD Trial Enrollment and Analyze Data to Assist in Phase 2 Design 2H2023 NGC-Cap: Define Regulatory Paths to Approval and ODR Phase 2 Design with FDA 2H2023 NGC-Cap: Submit ODR Phase 2 Protoc
Slide 12: Why Processa Now?
Why Processa Now? @ Provessa Pharmaceuticals * Upcoming Catalysts/Milestones: - PCS6422/NGC-Cap ~ Complete Phase 1B enrollment & dose regimen safety evaluation, ~ Finalize Phase 2 study design based on FDA feedback. ~ PCS3117/NGC-Gem ~ Collaborate with FDA to further define development program (targ
Slide 13: Company Summary
Company Summary @ Processa Pharmaceuticals Up-Side Opportunity with a Strategy of Optimizing Proven Therapeutics via NCEs * Developing Next-Generation Chemotherapy (NGC) drugs with near term achievable milestones using cancer-killing molecules presently in FDA-approved drugs. * NCEs with potential f
Slide 14: Processa Pharmaceuticals
q Processa Pharmaceuticals Investor & Media Relations: CORE IR processapharma.com
Processa Pharmaceuticals — Investor Presentation (October 2023) on 6ix